title: Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction.
authors.forename: T F
authors.initials: TF
authors.lastname: Roberts
authors.forename: K
authors.initials: K
authors.lastname: Sprague
authors.forename: D
authors.initials: D
authors.lastname: Schenkein
authors.forename: K B
authors.initials: KB
authors.lastname: Miller
authors.forename: V
authors.initials: V
authors.lastname: Relias
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000009:adverse effects*; D020520:Brain Infarction / Q000097:blood / Q000139:chemically induced / Q000209:etiology*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy; D007964:Leukocytosis / Q000139:chemically induced* / Q000150:complications; D010087:Oxides / Q000008:administration & dosage / Q000009:adverse effects*; D012008:Recurrence; D012074:Remission Induction / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide